Literature DB >> 7798213

Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction.

R M Schmid1, S Liptay, J C Betts, G J Nabel.   

Abstract

The NF-kappa B transcription factors display a high degree of sequence conservation in a domain initially described in the rel oncogene. Two family members, NF-kappa B1 and NF-kappa B2, have distinct DNA binding properties and functionally distinct effects on different enhancers. NF-kappa B1, for example, binds to the kappa B site from the human immunodeficiency virus (HIV) with approximately 15-fold higher affinity than NF-kappa B2. In this study, we have defined regions within the Rel domain which determine DNA binding specificity and interaction with other proteins. We find that the COOH-terminal putative Rel dimerization domain of NF-kappa B1 is required for preferential binding to the HIV kappa B site. In contrast, preferential stimulation of the HIV enhancer by NF-kappa B2 with RelA(p65) is determined by both the NH2- and COOH-terminal Rel domains of NF-kappa B2. These two regions of NF-kappa B2 also mediate preferential synergy with Bcl3. These data suggest that a specific subdomain of the Rel conserved region has evolved to control the fine specificity of DNA binding, and two distinct subregions within the Rel domain determine the specificity of interaction with other transcription factors. These specific Rel-conserved domains therefore determine the specificity of NF-kappa B interactions and contribute to selective gene activation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7798213

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Involvement of TFIID and USA components in transcriptional activation of the human immunodeficiency virus promoter by NF-kappaB and Sp1.

Authors:  M Guermah; S Malik; R G Roeder
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

2.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.

Authors:  C Wahl; S Liptay; G Adler; R M Schmid
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

3.  Differential regulation of NF-kappaB2(p100) processing and control by amino-terminal sequences.

Authors:  J C Betts; G J Nabel
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

4.  Structure of the human NF-kappaB p52 homodimer-DNA complex at 2.1 A resolution.

Authors:  P Cramer; C J Larson; G L Verdine; C W Müller
Journal:  EMBO J       Date:  1997-12-01       Impact factor: 11.598

5.  Transcriptional regulation of human polyomavirus JC: evidence for a functional interaction between RelA (p65) and the Y-box-binding protein, YB-1.

Authors:  G V Raj; M Safak; G H MacDonald; K Khalili
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa.

Authors:  F Oswald; S Liptay; G Adler; R M Schmid
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

7.  p300 acts as a transcriptional coactivator for mammalian Notch-1.

Authors:  F Oswald; B Täuber; T Dobner; S Bourteele; U Kostezka; G Adler; S Liptay; R M Schmid
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

8.  IL-10 increases tissue injury after selective intestinal ischemia/reperfusion.

Authors:  Natascha C Nüssler; Andrea R Müller; Hans Weidenbach; Athanasios Vergopoulos; Klaus P Platz; Hans-Dieter Volk; Peter Neuhaus; Andreas K Nussler
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

9.  Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site.

Authors:  K Verhoef; R W Sanders; V Fontaine; S Kitajima; B Berkhout
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 10.  Origin of the Functional Distinctiveness of NF-κB/p52.

Authors:  Gourisankar Ghosh; Vivien Ya-Fan Wang
Journal:  Front Cell Dev Biol       Date:  2021-11-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.